These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 32301297)

  • 1. Therapeutic Effects of Mesenchymal Stem Cells on a Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Model.
    Park SY; Oh IY; Kim JH; Kim HJ; Seo B; Kwon OY; Song WJ; Kwon HS; Cho YS; Moon HB; Kim TB
    J Korean Med Sci; 2020 Apr; 35(15):e130. PubMed ID: 32301297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients.
    Saito N; Yoshioka N; Abe R; Qiao H; Fujita Y; Hoshina D; Suto A; Kase S; Kitaichi N; Ozaki M; Shimizu H
    J Allergy Clin Immunol; 2013 Feb; 131(2):434-41.e1-9. PubMed ID: 23111236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management.
    Sane SP; Bhatt AD
    J Assoc Physicians India; 2000 Oct; 48(10):999-1003. PubMed ID: 11200928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases.
    Abe R
    J Dermatol Sci; 2008 Dec; 52(3):151-9. PubMed ID: 18657400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lamotrigine Emerging as a Driver of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An 8-Year Retrospective Study.
    Glahn JZ; Almeida MN; Kochen A; Noel O; Stogner V; Hsia HC; Savetamal A
    Burns; 2024 Nov; 50(8):2114-2123. PubMed ID: 39127578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry.
    Diphoorn J; Cazzaniga S; Gamba C; Schroeder J; Citterio A; Rivolta AL; Vighi GD; Naldi L;
    Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):196-203. PubMed ID: 26687641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nine years of a single referral center management of Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome).
    Monteiro D; Egipto P; Barbosa J; Horta R; Amarante J; Silva P; Silva A
    Cutan Ocul Toxicol; 2017 Jun; 36(2):163-168. PubMed ID: 27487073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [News in severe clinical adverse drug reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)].
    Martínez-Cabriales SA; Gómez-Flores M; Ocampo-Candiani J
    Gac Med Mex; 2015; 151(6):777-87. PubMed ID: 26581536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Stevens-Johnson syndrome and toxic epidermal necrolysis--updates and innovations].
    Halevy S
    Harefuah; 2010 Mar; 149(3):186-90, 193. PubMed ID: 20684173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children: 20 years study in a tertiary care hospital.
    Techasatian L; Panombualert S; Uppala R; Jetsrisuparb C
    World J Pediatr; 2017 Jun; 13(3):255-260. PubMed ID: 27650525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Harr T; French LE
    Chem Immunol Allergy; 2012; 97():149-66. PubMed ID: 22613860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand.
    Abe R; Shimizu T; Shibaki A; Nakamura H; Watanabe H; Shimizu H
    Am J Pathol; 2003 May; 162(5):1515-20. PubMed ID: 12707034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving mortality outcomes of Stevens Johnson syndrome/toxic epidermal necrolysis: A regional burns centre experience.
    Nizamoglu M; Ward JA; Frew Q; Gerrish H; Martin N; Shaw A; Barnes D; Shelly O; Philp B; El-Muttardi N; Dziewulski P
    Burns; 2018 May; 44(3):603-611. PubMed ID: 29029855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High risk and low prevalence diseases: Stevens Johnson syndrome and toxic epidermal necrolysis.
    van Nispen C; Long B; Koyfman A
    Am J Emerg Med; 2024 Jul; 81():16-22. PubMed ID: 38631147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management.
    Mockenhaupt M
    Semin Cutan Med Surg; 2014 Mar; 33(1):10-6. PubMed ID: 25037254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Fritsch PO; Sidoroff A
    Am J Clin Dermatol; 2000; 1(6):349-60. PubMed ID: 11702611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stevens-Johnson syndrome and toxic epidermal necrolysis: what do we know?
    Tartarone A; Lerose R
    Ther Drug Monit; 2010 Dec; 32(6):669-72. PubMed ID: 20844465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database: A subgroup approach to disproportionality analysis.
    Nguyen KD; Tran TN; Nguyen MT; Nguyen HA; Nguyen HA; Vu DH; Nguyen VD; Bagheri H
    J Clin Pharm Ther; 2019 Feb; 44(1):69-77. PubMed ID: 30129156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems Medicine.
    Chen CB; Wang CW; Chung WH
    Methods Mol Biol; 2022; 2486():37-54. PubMed ID: 35437717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results.
    Papp A; Sikora S; Evans M; Song D; Kirchhof M; Miliszewski M; Dutz J
    Burns; 2018 Jun; 44(4):807-815. PubMed ID: 29627131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.